Abstract
INTRODUCTION: Neoadjuvant chemotherapy (NeoCTX) is standard management for locally advanced breast cancer. Phase III clinical trials reveal equivalent survival and improved breast conservation surgery (BCS) eligibility in Stage II breast cancer patients receiving neoCTX compared to postoperative CTX. Controversy persists regarding optimal integration of sentinel lymph node biopsy (SLNBx) into neoCTX protocols. We evaluated evolving surgical practice patterns regarding neoCTX, BCS, and SLNBx for Stage II breast cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
